CD4 and neoplasm: Transfer of a small number of CD4 T cells into lymphopenic mice, in combination with CTLA-4 blockade (63) or CD137 agonist immunotherapy (78), resulted in potent rejection of large vascularized tumours, independent of other immune cells and in an MHCII-restricted manner.